State Street Corp Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

State Street Corp grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 2.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,854,314 shares of the biopharmaceutical company’s stock after buying an additional 99,802 shares during the quarter. State Street Corp owned 1.96% of Esperion Therapeutics worth $6,360,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ESPR. Wasatch Advisors LP increased its position in Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares during the period. MetLife Investment Management LLC increased its stake in Esperion Therapeutics by 47.1% during the 3rd quarter. MetLife Investment Management LLC now owns 71,050 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 22,734 shares during the period. BNP Paribas Financial Markets raised its position in shares of Esperion Therapeutics by 152.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 74,522 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth $94,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 295,378 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, December 12th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research note on Friday, December 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Price Performance

ESPR stock opened at $2.28 on Friday. Esperion Therapeutics, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The stock has a market capitalization of $449.24 million, a price-to-earnings ratio of -3.56 and a beta of 1.01. The business’s fifty day moving average price is $2.44 and its two-hundred day moving average price is $2.21.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.